Hui-Sheng Chen
10
3
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
10.0%
1 terminated/withdrawn out of 10 trials
83.3%
-3.2% vs industry average
20%
2 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK)
Role: lead
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)
Role: lead
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)
Role: lead
Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)
Role: lead
Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol
Role: lead
Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
Role: lead
Oxidation-reduction Homeostasis in Cognitive Impairment Patients After Stroke
Role: lead
Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）
Role: lead
Quality Control Project of Stroke in Liaoning Province
Role: lead
The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship
Role: lead
All 10 trials loaded